Bioxytran (BIXT) Long-Term Deferred Tax (2018 - 2025)
Bioxytran (BIXT) posted Long-Term Deferred Tax of $16.7 million for Q4 2025, up 437.95% sequentially from $3.1 million in Q4 2024, and up 437.95% YoY from $3.1 million in Q4 2024.
Bioxytran (BIXT) Long-Term Deferred Tax (2018 - 2025) Analysis & Trends
Bioxytran has reported Long-Term Deferred Tax for 8 years, with the latest figure at $16.7 million in Q4 2025.
- Quarterly Long-Term Deferred Tax rose 437.95% year-over-year to $16.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.7 million (up 437.95% YoY) and the FY2025 annual result came in at $16.7 million, up 437.95% from the prior year.
- Long-Term Deferred Tax rose to $16.7 million in Q4 2025 per BIXT's latest filing, from $3.1 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $16.7 million in Q4 2025 and troughed at $1.4 million in Q4 2021.
- A 5-year average of $5.2 million and a median of $2.7 million in 2023 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2021 and 2025: Long-Term Deferred Tax tumbled 56.6% in 2021, then surged 437.95% in 2025.
- Over 5 years, Long-Term Deferred Tax stood at $1.4 million in 2021, then jumped by 38.88% to $1.9 million in 2022, then soared by 41.28% to $2.7 million in 2023, then grew by 13.02% to $3.1 million in 2024, then soared by 437.95% to $16.7 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $16.7 million, $3.1 million, and $2.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - |
| 10 | Bioxytran | 2.29 Mn | 2.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.70 Mn |
| Dec 31, 2024 | 3.10 Mn |
| Dec 31, 2023 | 2.75 Mn |
| Dec 31, 2022 | 1.94 Mn |
| Dec 31, 2021 | 1.40 Mn |
| Dec 31, 2020 | 3.23 Mn |
| Dec 31, 2019 | 174,840.00 |
| Dec 31, 2018 | 226,660.00 |